For pre-clinical biotech, above all invest based on the Management team.
Every stock has a story. OWC Pharma has Dr. Yehuda Baruch. Dr. Baruch was Director of the Israeli Medical Use of Cannabis Program from 2003-2012. He was tapped for the job, he didn't seek it out. In fact, he wasn't truly pro MMJ until around 2005 when one of his cancer patients thank Dr. Baruch for letting him live out his final days with the dignity afforded the MMJ treatments.
As of 2012, Dr. Baruch had personally overseen the MMJ treatments of almost 14,000 patients.
Furthermore, OWC Pharma has been doing testing not just on CBD/THC combinations, but on combinations of "at least 8 cannabinoids and a few bioflavonoids". This is light years ahead of every other firm. (There is another cannabis biotech company, InMed, that is doing interesting things with the other cannabinoids today, but OWC Pharm has been testing these compounds for years. Years in biotech research is like dog years to human years.)
They key takeaway is OWCP is cannabis biotech. Over the long term, the big money is in tested, proven, precise, scientific delivery systems.
No legitimate doctor wants to tell a patient to "take two puffs and call me in the morning".
And taking CBD oils is akin to carpet bombing. What doctors and the FDA want is precise amounts of cannabinoids, in proven ratios, delivered to the blood stream. MMJ CBD oil is currently about carpet bombing, with OWC Pharma it will be about laser-guided missiles.
